奥希替尼致间质性肺病1例并文献复习

doi:10.3969/j.issn.2095-1264.2024.03.18

首页 > 过刊浏览>2024年第3期 >383-386. DOI:10.3969/j.issn.2095-1264.2024.03.18

奥希替尼致间质性肺病1例并文献复习
DOI:
                        10.3969/j.issn.2095-1264.2024.03.18
                    
作者:
                        
                        
                    
作者单位:1.锡林郭勒盟中心医院，药学部，内蒙古 锡林浩特，026000;2.锡林郭勒盟中心医院，影像科，内蒙古 锡林浩特，026000;3.锡林郭勒盟中心医院，微创介入科，内蒙古 锡林浩特，026000
作者简介:李春梅，女，硕士，副主任药师，研究方向：临床药学。
通讯作者:代亚军，女，学士，主任药师，研究方向：医院药学。
中图分类号:R734.2;R730.6
基金项目:

A case of interstitial lung disease caused by osimertinib mesylate and literature review

Author:

Affiliation:

1.Department of Pharmacy,;2.Department of Imaging,;3.Department of Minimally Invasive Intervention, Xilin Gol League Central Hospital, Xilinhot, 026000, Inner Mongolia, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

报道1例65岁表皮生长因子受体19外显子缺失突变（E746_A750del）的右下肺腺癌患者，在服用奥希替尼100天后出现间质性肺病。停药后给予吸氧、糖皮质激素治疗后好转，尝试使用盐酸厄洛替尼片，未再发生间质性肺病。

Abstract:

This report presents a case of a 65-year-old patient with a right lower lobe adenocarcinoma of the lung, who had an exon 19 deletion mutation (E746_A750del) in the epidermal growth factor receptor (EGFR) gene and developed interstitial lung disease after taking osimertinib for 100 days. The patient improved after discontinuing osimertinib and receiving oxygen and glucocorticoid treatment. Then the patient tried erlotinib hydrochloride tablets, and interstitial lung disease did not occur again.